ATE443264T1 - Verfahren zur verwendung von quantitativen lipidmetabolondaten - Google Patents

Verfahren zur verwendung von quantitativen lipidmetabolondaten

Info

Publication number
ATE443264T1
ATE443264T1 AT02782079T AT02782079T ATE443264T1 AT E443264 T1 ATE443264 T1 AT E443264T1 AT 02782079 T AT02782079 T AT 02782079T AT 02782079 T AT02782079 T AT 02782079T AT E443264 T1 ATE443264 T1 AT E443264T1
Authority
AT
Austria
Prior art keywords
quantitative
data
metabolone
lipide
markers
Prior art date
Application number
AT02782079T
Other languages
English (en)
Inventor
Steven Watkins
Original Assignee
Lipomics Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26984604&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE443264(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lipomics Technologies Inc filed Critical Lipomics Technologies Inc
Application granted granted Critical
Publication of ATE443264T1 publication Critical patent/ATE443264T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AT02782079T 2001-09-24 2002-09-24 Verfahren zur verwendung von quantitativen lipidmetabolondaten ATE443264T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32472801P 2001-09-24 2001-09-24
US35212902P 2002-01-25 2002-01-25
PCT/US2002/030348 WO2003028271A2 (en) 2001-09-24 2002-09-24 Methods of using quantitative lipid metabolome data

Publications (1)

Publication Number Publication Date
ATE443264T1 true ATE443264T1 (de) 2009-10-15

Family

ID=26984604

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02782079T ATE443264T1 (de) 2001-09-24 2002-09-24 Verfahren zur verwendung von quantitativen lipidmetabolondaten

Country Status (8)

Country Link
US (2) US20050009005A1 (de)
EP (1) EP1438420B1 (de)
AT (1) ATE443264T1 (de)
AU (1) AU2002348574A1 (de)
CA (1) CA2459508A1 (de)
DE (1) DE60233743D1 (de)
DK (1) DK1438420T3 (de)
WO (1) WO2003028271A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003078574A2 (en) * 2002-03-11 2003-09-25 Lipomics Technologies, Inc. Novel metabolic targets and markers
EP1789806A2 (de) * 2004-09-13 2007-05-30 Lipomics Technologies, Inc. Metabolitmarkierer zur gewichtsverwaltung
US8637321B2 (en) * 2005-10-24 2014-01-28 Duke University Lipidomics approaches for central nervous system disorders
CN103217520A (zh) * 2006-02-27 2013-07-24 靶向分子诊断有限责任公司 用于减少细胞脂肪和预测用酪氨酸激酶抑制剂治疗后的心脏毒性的组合物和方法
EP2369346B1 (de) * 2006-03-24 2014-08-27 Metanomics GmbH Verfahren zur Diagnose von Diabetes Typ II
US8137977B2 (en) * 2006-04-24 2012-03-20 Children's Hospital & Research Center At Oakland Lipidomic approaches to determining drug response phenotypes in cardiovascular disease
EP2021512A4 (de) 2006-05-08 2009-08-05 Tethys Bioscience Inc Systeme und verfahren zur entwicklung diagnostischer tests auf der basis von biomarkerinformationen aus hinterlassenen klinischen probensätzen
WO2007144467A1 (en) * 2006-06-12 2007-12-21 Zora Biosciences Oy Diagnostic method for myopathy
EP3285072B1 (de) * 2006-08-08 2020-04-15 Metabolon, Inc. Marker von nichtalkoholischer fettlebererkrankung (nafld) und nichtalkoholischer steatohepatitis (nash) sowie verfahren zur verwendung davon
CN101802620A (zh) * 2007-02-22 2010-08-11 特提斯生物科学公司 糖尿病状况的代谢标志物及其使用方法
EP2279734A4 (de) * 2008-05-20 2013-05-01 Mochida Pharm Co Ltd Zusammensetzung zur verhinderung eines kardiovaskulären ereignisses bei hochrisikopatienten
CA2724422A1 (en) 2008-05-28 2009-12-23 Basf Se Means and methods for assessing increased peroxisomal proliferation
WO2010028336A2 (en) * 2008-09-08 2010-03-11 President And Fellows Of Harvard College Fatty acid c16:1n7-palmitoleate a lipokine and biomarker for metabolic status
WO2011063470A1 (en) * 2009-11-27 2011-06-03 Baker Idi Heart And Diabetes Institute Holdings Limited Lipid biomarkers for stable and unstable heart disease
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
CA2798330A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
WO2012051463A2 (en) * 2010-10-14 2012-04-19 The Regents Of The University Of California Urine metabolomic profile of diabetic kidney disease
CN102789536B (zh) * 2011-05-20 2015-11-18 中国人民解放军第二军医大学 肝脏手术治疗风险无创评估模型的建立方法
WO2014143080A1 (en) * 2013-03-15 2014-09-18 Beyond Obesity Llc Methods for generating personalized dietary guidance using fatty acids for purposes of reducing risk of pathology
US20160356798A1 (en) * 2013-12-20 2016-12-08 Metabolon, Inc. Biomarkers of de novo lipogenesis and methods using the same
WO2017070114A2 (en) * 2015-10-18 2017-04-27 Wei Jia Diabetes-related biomarkers and treatment of diabetes-related conditions
WO2018119339A1 (en) * 2016-12-23 2018-06-28 Virta Health Corp. Methods of rationally designing a personalized nutritional plan
KR102163693B1 (ko) * 2018-09-27 2020-10-12 차의과학대학교 산학협력단 노화 및 항노화 바이오마커 및 그의 용도
CN112255333B (zh) * 2020-09-28 2022-07-22 复旦大学 卵巢肿瘤尿液代谢标志物及其应用
WO2023137449A2 (en) * 2022-01-13 2023-07-20 Purdue Research Foundation Methods of assessing carcass muscle biomarkers to discriminate characteristics of the meat

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847550A (en) * 1973-03-27 1974-11-12 Atomic Energy Commission Differential chromatographic method
US5075101A (en) * 1990-04-10 1991-12-24 Siguel Edward N Method for diagnosis of fatty acid or lipid abnormalities
US5773300A (en) * 1995-05-18 1998-06-30 Cell Therapeutics, Inc. Neoplasia diagnostic method
US6188783B1 (en) * 1997-07-25 2001-02-13 Affymetrix, Inc. Method and system for providing a probe array chip design database
US6223127B1 (en) * 1997-08-15 2001-04-24 Affymetrix, Inc. Polymorphism detection utilizing clustering analysis
US6185561B1 (en) * 1998-09-17 2001-02-06 Affymetrix, Inc. Method and apparatus for providing and expression data mining database
WO2000051054A1 (en) * 1999-02-26 2000-08-31 Lipomed, Inc. Methods, systems, and computer program products for analyzing and presenting risk assessment results based on nmr lipoprotein analysis of blood
WO2003005628A2 (en) * 2001-07-06 2003-01-16 Lipomics Technologies, Inc. Generating, viewing, interpreting, and utilizing a quantitative database of metabolites
WO2003078574A2 (en) * 2002-03-11 2003-09-25 Lipomics Technologies, Inc. Novel metabolic targets and markers

Also Published As

Publication number Publication date
WO2003028271A3 (en) 2004-04-01
DE60233743D1 (de) 2009-10-29
EP1438420A2 (de) 2004-07-21
US20050009005A1 (en) 2005-01-13
EP1438420B1 (de) 2009-09-16
WO2003028271A2 (en) 2003-04-03
CA2459508A1 (en) 2003-04-03
EP1438420A4 (de) 2006-09-06
US20090239253A1 (en) 2009-09-24
WO2003028271A9 (en) 2004-06-24
AU2002348574A1 (en) 2003-04-07
DK1438420T3 (da) 2010-01-18

Similar Documents

Publication Publication Date Title
ATE443264T1 (de) Verfahren zur verwendung von quantitativen lipidmetabolondaten
CY1107733T1 (el) Μεθοδος για τον χαρακτηρισμο μιας βιολογικης καταστασης χρησιμοποιωντας βαθμοnομημενα προφιλ γονιδιακης εκφρασης
ATE378420T1 (de) Mediator-stabilisierende verbindung und methoden zur verwendung zur detektion elektrochemischer analyte
MXPA02010106A (es) Determinacion de suficiencia de volumen de muestra en dispositivos biosensores.
ATE449961T1 (de) Elektrochemischer teststreifen zur verwendung bei der analyten-bestimmung
EP1312919A3 (de) Probevolumen-Messapparat
MX2010000972A (es) Sistema y metodos que determinan concentracion de analito utilizando amperometria resuelta en tiempo.
EA200601415A1 (ru) Сочетание реагентов и способ непосредственного измерения при комнатной температуре содержания холестерина липопротеинов низкой плотности с использованием индикаторной полоски
EP2333541A3 (de) Verfahren und Materialien zur Identifikation der Hundeart
EP2405022A3 (de) Genexpressionsprofilierung zur Vorhersage der Überlebensfähigkeit von Prostatakrebspatienten
DE60332639D1 (de) Verwendung von biomarkern zum nachweis von eierstockkrebs
DE69920937D1 (de) Verfahren zur quantifizierung von cholesterol in lipoproteinen und quantifizierungsreagenzien
IS7611A (is) Örfylki og aðferð til þess að framkvæma blöndunarhvörf fyrir fjölda sýna á einu örfylki
WO2004113909A8 (en) System and method for coding information on a biosensor test strip
DE60325482D1 (de) Verfahren zur charakterisierung von biomolekülen mittels resultat-gesteuerter strategie
WO2007038754A3 (en) Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
WO2004013610A3 (en) Method of measuring molecular interactions
ATE510492T1 (de) Verfahren zur kennzeichnung von geweben
WO2004055491A3 (en) Novel method for sequence determination using nmr
DK1495105T3 (da) Substrat og fremgangsmåde til måling af elektrofysiologiske egenskaber for cellemenbraner
WO2007027200A3 (en) A method and system for generating a valuation metric based on growth data factors
WO2004061419A3 (en) Systems and methods for estimating properties of a sample
ATE456797T1 (de) Verwendung von nogo-c bei der beurteilung von herzversagen
DE60221550D1 (de) Methode zur bestimmung der zellzyklusposition
DE50200087D1 (de) Computersystem und Verfahren zur Datenerfassung für die Ermittlung des Verlaufs einer chronischen Erkrankung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties